Cediranib

Generic Name: Cediranib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₅H_₂₇FN_₄O_₃

CAS Number: 288383-20-0

Unique Ingredient Identifier: NQU9IPY4K9

Background: The novel indole-ether quinazoline Cediranib is a highly potent (IC < 1 nmol/L) ATP-competitive inhibitor of recombinant KDR tyrosine kinase in vitro. It is being developed clinically as a once-daily oral therapy for the treatment of cancer.

Indication: For the treatment of liver cancer, advanced non-small cell lung cancer (NSCLC), advanced colorectal cancer (CRC) and other solid tumors.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Adult Solid Neoplasm
Male Breast Carcinoma
Recurrent Pancreatic Carcinoma
Adult Glioblastoma
Adult Mixed Glioma
Recurrent Breast Carcinoma
Recurrent Renal Cell Carcinoma
Stage III Renal Cell Cancer
Stage IIIA Non-Small Cell Lung Cancer
Adult Gliosarcoma

Interventions: Drug: Gamma-Secretase Inhibitor RO4929097
Drug: Cediranib Maleate
Other: Pharmacological Study
Other: Laboratory Biomarker Analysis

First Posted Date: 2010-05-26

Last Posted Date: 2014-12-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 20

Registration Number: NCT01131234

Locations: 🇨🇦
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
🇨🇦
University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada

Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer

Phase 1

Active, not recruiting

Conditions: Ovarian High Grade Serous Adenocarcinoma
Ovarian Endometrioid Adenocarcinoma
Ovarian Serous Adenocarcinoma
Triple-Negative Breast Carcinoma
Fallopian Tube Carcinoma
Primary Peritoneal Serous Adenocarcinoma
Ovarian Serous Surface Papillary Adenocarcinoma

Interventions: Procedure: Biopsy
Procedure: Biospecimen Collection
Drug: Cediranib Maleate
Procedure: Computed Tomography
Procedure: Echocardiography
Procedure: Magnetic Resonance Imaging
Procedure: Multigated Acquisition Scan
Drug: Olaparib

First Posted Date: 2010-05-05

Last Posted Date: 2024-10-31

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 155

Registration Number: NCT01116648

Locations: 🇺🇸
National Cancer Institute, Rockville, Maryland, United States
🇺🇸
Massachusetts General Hospital, Charlestown, Massachusetts, United States
🇺🇸
Newton-Wellesley Hospital, Newton, Massachusetts, United States

and more 11 locations

Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma

Phase 1

Active, not recruiting

Conditions: Sarcomatoid Mesothelioma
Pleural Malignant Mesothelioma
Recurrent Malignant Mesothelioma
Epithelioid Mesothelioma

Interventions: Drug: Cediranib Maleate
Other: Laboratory Biomarker Analysis
Drug: Cisplatin
Drug: Pemetrexed Disodium
Other: Placebo Administration

First Posted Date: 2010-02-08

Last Posted Date: 2024-11-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 117

Registration Number: NCT01064648

Locations: 🇺🇸
Heartland Cancer Research NCORP, Decatur, Illinois, United States
🇺🇸
Crossroads Cancer Center, Effingham, Illinois, United States
🇺🇸
Illinois CancerCare-Eureka, Eureka, Illinois, United States

and more 228 locations

Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed Glioblastoma

Phase 2

Completed

Conditions: Adult Glioblastoma
Adult Gliosarcoma

Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy
Radiation: Intensity-Modulated Radiation Therapy
Drug: Cediranib Maleate
Other: Laboratory Biomarker Analysis
Other: Placebo Administration
Drug: Temozolomide

First Posted Date: 2010-02-04

Last Posted Date: 2022-07-26

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 261

Registration Number: NCT01062425

Locations: 🇺🇸
University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States
🇺🇸
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸
Rush University Medical Center, Chicago, Illinois, United States

and more 102 locations

Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma

Phase 1

Completed

Conditions: Adult Glioblastoma
Adult Gliosarcoma
Recurrent Adult Brain Neoplasm
Adult Giant Cell Glioblastoma

Interventions: Drug: Cediranib Maleate
Drug: Cilengitide
Other: Laboratory Biomarker Analysis

First Posted Date: 2009-09-18

Last Posted Date: 2015-04-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 47

Registration Number: NCT00979862

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Emory University/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
Massachusetts General Hospital, Charlestown, Massachusetts, United States

and more 8 locations

Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma

Phase 2

Active, not recruiting

Conditions: Sarcoma, Alveolar Soft Part

Interventions: Drug: AZD2171

First Posted Date: 2009-07-21

Last Posted Date: 2024-03-12

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 53

Registration Number: NCT00942877

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer

Phase 1

Terminated

Conditions: Stage IV Breast Cancer
Stage IV Renal Cell Cancer
Stage IV Non-small Cell Lung Cancer
Stage IVA Colon Cancer
Stage IVA Rectal Cancer
Stage IVB Rectal Cancer
Male Breast Cancer
Stage IVB Colon Cancer
Stage IV Melanoma
Tumors Metastatic to Brain

Interventions: Drug: cediranib maleate
Radiation: whole-brain radiation therapy

First Posted Date: 2009-07-13

Last Posted Date: 2013-03-08

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 18

Registration Number: NCT00937482

Locations: 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

Phase 1

Completed

Conditions: Adult Giant Cell Glioblastoma
Adult Glioblastoma
Adult Gliosarcoma

Interventions: Drug: Cediranib Maleate
Procedure: Diffusion Tensor Imaging
Procedure: Diffusion Weighted Imaging
Procedure: Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Radiation: Fludeoxyglucose F-18
Radiation: Intensity-Modulated Radiation Therapy
Other: Laboratory Biomarker Analysis
Procedure: Perfusion Magnetic Resonance Imaging
Procedure: Positron Emission Tomography
Drug: Temozolomide

First Posted Date: 2008-04-21

Last Posted Date: 2023-06-06

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 46

Registration Number: NCT00662506

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

Docetaxel and Prednisone With or Without Cediranib in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

Phase 2

Terminated

Conditions: Adenocarcinoma of the Prostate
Stage IV Prostate Cancer

Interventions: Drug: cediranib maleate
Drug: docetaxel
Drug: prednisone
Other: laboratory biomarker analysis

First Posted Date: 2007-09-10

Last Posted Date: 2018-08-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 57

Registration Number: NCT00527124

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
🇺🇸
Wayne State University, Detroit, Michigan, United States

and more 1 locations

Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Phase 2

Completed

Conditions: Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Secondary Acute Myeloid Leukemia
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
de Novo Myelodysplastic Syndromes
Secondary Myelodysplastic Syndromes
Recurrent Adult Acute Myeloid Leukemia
Untreated Adult Acute Myeloid Leukemia
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)

Interventions: Drug: cediranib maleate
Other: laboratory biomarker analysis

First Posted Date: 2007-05-17

Last Posted Date: 2017-02-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 39

Registration Number: NCT00475150

Locations: 🇺🇸
Johns Hopkins University/Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸
Howard University Hospital, Washington, District of Columbia, United States

and more 2 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy